Key information

🔎 Fund Overview

Travere Therapeutics Inc. is a biopharmaceutical company. The Company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. The Company’s products include Chenodal (chenodiol tablets), Cholbam (cholic acid capsules), and Thiola and Thiola EC (tiopronin tablets). Chenodal, which is for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Cholbam, which is for the treatment of bile acid synthesis disorders due to single enzyme defects. Thiola and Thiola EC, which are for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. The Company's lead clinical program includes FILSPARI to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression and Sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS).